CeloNova BioSciences has announced the strategic decision to focus its core business on creating partnership and co-development opportunities with medical device manufacturers seeking to optimise implant interaction within the body.
The company’s nanocoated innovation is the result of years of rigorous scientific research and engineering and has been extensively published in numerous academic articles to date, CeloNova said in a press release.
“We are pleased to offer leading medical device manufacturers access to the unique clinical advantages of our Polyzene-F nanocoated technology that has clinically demonstrated low thrombosis, restenosis and inflammation with rapid healing effects,” stated Carl St Bernard, president and chief executive officer of CeloNova. “This technology offers a significant benefit to companies seeking to improve the clinical performance of their implant technologies.”
“I fully support CeloNova’s new strategic direction which allows medical device manufacturers to benefit from long-term biocompatibility and thromboresistance of Polyzene-F,” stated Michael Grunze (Ruprecht-Karls-University, Heidelberg, Germany) and co-inventor of Polyzene-F. “When my students and I set out to study the haemocompatibility of this inorganic polymer in our lab in Heidelberg Germany, we soon realised its potential to significantly limit a wide range of implant complications and being broadly applied in the human body and in biomedical devices.”
CeloNova is based on a rich history of medical innovation with two PzF coated medical implants successfully commercialized in the USA and the EU. The company’s PzF coated embolic microspheres product line was sold to Boston Scientific in 2015 and the COBRA PzF NanoCoated coronary stent, was developed to safely and effectively treat patients who may benefit from one-month of dual antiplatelet therapy.
Polyzene-F is a proprietary, ultra-pure and highly elastic surface coating possessing unique mechanical properties that allow an implant to be coated at a nanoscale level. The coating acts as a biocompatible barrier between the implant, intimal surface and circulating elements in the blood and has demonstrated thromboresistant and anti-inflammatory properties with significantly faster, higher quality healing compared to market-leading technologies.